The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 462-469

  Kwon, Jisoo A ^a   Iversen, Jenny ^a   Maher, Lisa ^a   Law, Matthew G ^a   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Australia; HCV; HIV; Injecting drug users; Mathematical model; Needle and syringes

Indexed keywords

ARTICLE; AUSTRALIA; DRUG USE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MORBIDITY; NEEDLE; PRIORITY JOURNAL; SYRINGE; VIRUS TRANSMISSION;

AUSTRALIA; HEPATITIS C; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 68049118599     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181a2539a     Document Type: Article

References (55)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1-16. (Pubitemid 30421405)
2. WHO, UNAIDS. AIDS epidemic update: December 2007: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2007. Geneva, Switzerland.
3. McDonald A. Annual Surveillance Report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia: National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW; 2007.
4. Iversen J, Topp L, Maher L. Australian NSP Survey National Data Report 2002 - 2006. National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW: University of New South Wales; 2007.
5. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust. 1997;167:17-20.
6. Dore GJ, Law M, MacDonald M, et al. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol. 2003;26:171-184. (Pubitemid 36206602)
7. Loxley WM, Phillips M, Carruthers SJ, et al. The Australian Study of HIV and Injecting Drug Use. Part I: prevalence for HIV, hepatitis B and hepatitis C among injecting drug users in four Australian cities. Drug Alcohol Rev. 1997;16:207-214.
8. Marsh A, Loxley W, Hawks D, et al. Changes in drug use and HIV/AIDS risk-taking 1989-1990. Drug Alcohol Rev. 1995;14:201-212.
9. Razali K, Thein HH, Bell J, et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007;91:228-235. (Pubitemid 47539727)
10. Kaldor JM, Archer GT, Buring ML, et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med J Aust. 1992;157: 227-230.
11. Strasser SI, Watson KJ, Lee CS, et al. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection. Med J Aust. 1995;162:355-358.
12. Roman F, Hawotte K, Struck D, et al. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol. 2008;14:1237-1243.
13. Hope V, Ncube F, DeSouza-Thomas L, et al. Shooting Up. Infections Among Injecting Drug Users in the United Kingdom 2003. London, United Kingdom: Health Protection Agengy; 2004.
14. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10:315-336. (Pubitemid 38072766)
15. Patz JA, Jodrey D. Occupational health in surgery: risks extend beyond the operating room. Aust N Z J Surg. 1995;65:627-629.
16. Kaplan EH, O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces. 1993;23:7-26.
17. Hudgens MG, Longini IM Jr, Vanichseni S, et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol. 2002; 155:159-168. (Pubitemid 34072739)
18. Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med. 1990; 113:740-746.
19. Cavalcante NJ, Abreu ES, Fernandes ME, et al. Risk of health care professionals acquiring HIV infection in Latin America. AIDS Care. 1991;3:311-316.
20. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994;170:1410-1417. (Pubitemid 24979098)
21. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med. 1993;153:1451-1458.
22. Nelsing S, Nielsen TL, Nielsen JO. Occupational exposure to human immunodeficiency virus among health care workers in a Danish hospital. J Infect Dis. 1994;169:478. (Pubitemid 24045623)
23. Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med. 1993;118:913-919.
24. Short LJ, Bell DM. Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. Am J Infect Control. 1993;21:343-350.
25. Gerberding JL. Management of occupational exposures to blood-borne viruses. N Engl J Med. 1995;332:444.
26. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev. 1996;18:137-148. (Pubitemid 27082085)
27. Kiyosawa K, Sodeyama T, Tanaka E, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med. 1991;115: 367-369.
28. Sodeyama T, Kiyosawa K, Urushihara A, et al. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents. Arch Intern Med. 1993;153:1565-1572. (Pubitemid 23205855)
29. Des Jarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000;90:1112-1116.
30. Donoghoe MC, Stimson GV, Dolan K, et al. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. AIDS. 1989;3:267-272. (Pubitemid 19167467)
31. Donoghoe MC, Dolan KA, Stimson GV. Life-style factors and social circumstances of syringe sharing in injecting drug users. Br J Addict. 1992;87:993-1003.
32. McKeganey N, Abel M, Taylor A, et al. The preparedness to share injecting equipment: an analysis using vignettes. Addiction. 1995;90: 1253-1260.
33. Australian National Council on drugs (ANCD). Needle and Syringe Programs: position paper. Canberra: ACT: 2002.
34. Return on Investment in Needle and Syringe Programs in Australia Report. Sydney, Australia: Commonwealth Department of Health and Ageing, Health Outcomes International Pvt Ltd, National Centre in HIV Epidemiology and Clinical Research; 2002.
35. Greenhalgh D, Hay G. Mathematical modelling of the spread of HIV/ AIDS amongst injecting drug users. IMA J Math Appl Med Biol. 1997;14: 11-38. (Pubitemid 127463788)
36. Blower SM, Hartel D, Dowlatabadi H, et al. Drugs, sex and HIV: a mathematical model for New York City. Philos Trans R Soc Lond B Biol Sci. 1991;331:171-187.
37. Murray JM, Law MG, Gao Z, et al. The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol. 2003;32:708-714. (Pubitemid 37304626)
38. Bacaër N, Abdurahman X, Ye J. Modeling the HIV/AIDS epidemic among injecting drug users and sex workers in Kunming, China. Bull Math Biol. 2006;68:525-550.
39. Vickerman P, Hickman M, Rhodes T, et al. Model projections on the required coverage of syringe distribution to prevent HIVepidemics among injecting drug users. J Acquir Immune Defic Syndr. 2006;42:355-361. (Pubitemid 44050015)
40. Siegel J, Weinstein M, Fineberg H. Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991;81:1273-1279.
41. Kretzschmar M, Wiessing L. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users. AIDS. 2008;22:1527-1537.
42. Sutton AJ, Gay NJ, Edmunds WJ. Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales. Vaccine. 2006;24:2377-2386.
43. Sutton AJ, Gay NJ, Edmunds WJ, et al. Modelling the hepatitis B vaccination programme in prisons. Epidemiol infect. 2006;134: 231-242.
44. Sutton AJ, Gay NJ, Edmunds WJ, et al. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006;6:93.
45. Abdala N, Gleghorn AA, Carney JM, et al. Can HIV-1-Contaminated Syringes Be Disinfected? Implications for Transmission Among Injection Drug Users. J Acquire Immune Defic Syndr. 2001;28:487-494. (Pubitemid 34033202)
46. Hagan H, Thiede H. Does bleach disinfection of syringes help prevent hepatitis C virus transmission. Epidemiology. 2003;14:628-629.
47. Agolini G, Russo A, Clementi M. Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. Am J Infect Control. 1999;27:236-239. (Pubitemid 29277951)
48. Kapadia F, Vlahov D, Des Jarlais DC, et al. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology. 2002;13:738.
49. Syringe Disinfection for Injection Drug Users. Centers for Disease Control and Prevention; 2007. Available at: http://www.cdc.gov/idu/facts/ disinfection.htm. Accessed June 2, 2008.
50. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust. 1999;170:220-221. (Pubitemid 29112652)
51. Hoare A, Regan DG, Wilson DP. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theor Biol Med Model. 2008;5:4.
52. National Notifiable Diseases Surveillance System. Australian Government Department of Health and Ageing (AGDHA). Vol 2006. Available at: http://www9.health.gov.au/cda/Source/CDA-index.cfm. Accessed June 12, 2008.
53. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press; 1991.
54. Maher L, Jalaludin B, Chant KG, et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101:1499-1508. (Pubitemid 44337774)
55. 2007 National Drug Strategy Household Survey: First Results. Canberra, Australia: Australian Institute of Health and Welfare; 2008.